Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Equillium (EQ – Research Report) on January 4 and set a price target of $14.00. The company’s shares closed last Thursday at $5.72, close to its 52-week low of $2.20.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 13.5% and a 51.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Equillium with a $14.67 average price target.
The company has a one-year high of $27.05 and a one-year low of $2.20. Currently, Equillium has an average volume of 1.4M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.